M L Vitovskaya studies tuberculosis, a serious bacterial infection that primarily affects the lungs. Her research specifically targets drug-resistant strains of TB, examining their effects on health and how effective different chemotherapy treatments are against them. She has investigated how some TB strains can cause more severe illness than others, which is crucial for developing better treatment strategies for patients suffering from this condition. Her findings provide valuable insights for doctors and researchers looking to combat the growing issue of TB resistance and improve patient outcomes.
Key findings
In a 2025 study, the highly virulent Beijing 396 strain of TB caused the most lung damage in treated mice, while the Beijing 6691 and LAM 7074 strains were easier to manage.
Mice infected with the Buryatia strain of TB faced a 100% mortality rate during testing, demonstrating the extreme lethality of certain strains.
After nearly six months of chemotherapy treatment, the bacterial load in lungs of most treated mice had slightly increased, indicating challenges in completely clearing the TB infection.
Frequently asked questions
Does Dr. Vitovskaya study drug-resistant tuberculosis?
Yes, Dr. Vitovskaya focuses on various drug-resistant strains of tuberculosis and their treatment.
What treatments has Dr. Vitovskaya researched?
She has researched the effectiveness of new chemotherapy drugs against different strains of tuberculosis.
Is Dr. Vitovskaya's work relevant to patients with drug-resistant TB?
Yes, her findings are crucial for developing better treatment strategies for patients suffering from drug-resistant tuberculosis.
Publications in plain English
Long-term chemotherapy of C57BL/6 mice infected with epidemiologically important Mycobacterium tuberculosis strains and molecular insight into host-pathogen interplay.
2025
Microbial pathogenesis
Vinogradova T, Zabolotnykh N, Dogonadze M, Dyakova M, Esmedlyaeva D +6 more
Plain English This study looked at how effective new chemotherapy drugs are against different strains of drug-resistant tuberculosis (TB) bacteria in mice. The researchers found that while treatment helped reduce lung damage and inflammation overall, some strains caused more serious illness than others: the highly virulent Beijing 396 strain resulted in the most lung damage, while the less harmful Beijing 6691 and LAM 7074 strains were easier to treat. Interestingly, after nearly six months of treatment, the bacterial load in the lungs of most treated mice increased slightly, highlighting the challenges in fully clearing the infection.
Who this helps: This research assists doctors and researchers in developing better treatment strategies for patients with drug-resistant TB.
Plain English This study looked at a new vaccine called TB/FLU-06E that may improve treatment for both regular and drug-resistant tuberculosis (TB) in mice. The research found that using this vaccine alongside standard therapy increased survival rates and lowered bacteria levels in the lungs, with a notable decrease of 1.83 logs for regular TB and 0.93 logs for drug-resistant TB. These findings are significant because they show that this vaccine can make existing TB treatments more effective, especially for those with drug-resistant forms of the disease.
Who this helps: This helps patients with tuberculosis, particularly those with drug-resistant strains.
A multifaceted interplay between virulence, drug resistance, and the phylogeographic landscape of.
2023
Microbiology spectrum
Mokrousov I, Vinogradova T, Dogonadze M, Zabolotnykh N, Vyazovaya A +3 more
Plain English This study focused on different strains of a type of tuberculosis known as Latin-American-Mediterranean (LAM) to understand their behavior and how they respond to treatment. Researchers found that a highly virulent strain that is sensitive to drugs has become more common, while a previously concerning multidrug-resistant strain has almost disappeared. This is important because it shows that the characteristics of these strains can change over time, highlighting the need for careful monitoring and tailored treatment strategies for tuberculosis.
Who this helps: This benefits patients and doctors by informing better treatment options and monitoring strategies for tuberculosis.
Extremely lethal and hypervirulentstrain cluster emerging in Far East, Russia.
2021
Emerging microbes & infections
Vinogradova T, Dogonadze M, Zabolotnykh N, Badleeva M, Yarusova I +8 more
Plain English This research focused on two dangerous strains of tuberculosis bacteria found in Eastern Russia. The study revealed that one strain (from Buryatia) caused higher mortality rates in mice, leading to 100% death in tested groups, while the other strain (from Omsk) was less harmful. These findings are important because they highlight the emergence of particularly lethal strains of tuberculosis that are resistant to multiple drugs, which could pose a significant threat to public health in the region.
Who this helps: This information benefits public health officials and doctors dealing with tuberculosis in affected areas.
[Preclinical and clinical trials of the new tuberculosis drug perchlozon].
2016
Terapevticheskii arkhiv
Yablonskiy PK, Vinogradova TI, Levashev YN, Pavlova MV, Zilber EK +6 more
Plain English The study looked at a new tuberculosis (TB) drug called perchlozon to see how well it works and how safe it is for patients with respiratory TB. The trials showed that using perchlozon as part of treatment shortened the time it takes to show improvement in patients with drug-resistant TB, which is tougher to treat. This is important because TB caused by drug-resistant strains is becoming more common, and perchlozon offers hope for patients who have limited treatment options.
Who this helps: This helps patients with severe, drug-resistant tuberculosis.
[Immunotropic and antihypoxant therapy of experimental drug-sensitive and drug-resistant tuberculosis].
2013
Patologicheskaia fiziologiia i eksperimental'naia terapiia
Sukhanov DS, Vinogradova TI, Demidik SN, Zabolotnyh NV, Vasilieva SN +2 more
Plain English This study looked at three treatments—cycloferon, remaxol, and runihol—for tuberculosis in a lab setting, focusing on both drug-sensitive and drug-resistant strains. The researchers found that cycloferon and remaxol significantly improved treatment effectiveness, leading to better lung health and reduced inflammation, while runihol did not help the treatment at all. This research is important because it shows how certain therapies can enhance recovery from tuberculosis, offering new hope for effective treatment options.
Who this helps: This helps patients suffering from tuberculosis, particularly those with drug-resistant forms.